Trump administration postpones rule on imported prescription drugs
The Trump administration has delayed by 90 days a federal rule that could limit Americans' access to prescription medicines from licensed international pharmacies. The rule could affect imports from Canada and other countries. The delay gives more time before the restriction takes effect.
The postponement concerns a federal rule that could restrict access to prescription medicines obtained through licensed international pharmacies. According to the available summary, the rule could affect imports from Canada and other countries. The administration has delayed it by 90 days, creating more time before any restriction would take effect. Because the material is limited, the story sits within the broader topic of how patients access medicines and how import rules are timed.
The delay may matter most to Americans who use licensed international pharmacies, including those seeking medicines from Canada or elsewhere. For the next 90 days, current access could remain unchanged. If the rule later takes effect, some patients might face fewer import options, possible cost changes, or the need to find alternatives. The full impact is uncertain and could depend on how the rule is ultimately applied.